Trial Profile
An Open-label Study of Nelotanserin in Patients With Lewy Body Dementia Who Have Frequent Visual Hallucinations or REM Sleep Behavior Disorder
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 15 Dec 2020
Price :
$35
*
At a glance
- Drugs Nelotanserin (Primary)
- Indications REM-sleep-behavior-disorder
- Focus Adverse reactions; Therapeutic Use
- Sponsors Sio Gene Therapies [CEASED]
- 10 Dec 2018 According to an Axovant media release, based on the data of the pilot study (RVT102-2002) , which did not meet the primary endpoint, the company has discontinued the clinical development of the Nelotanserin for the treatment of REM sleep behavior disorder (RBD) in patients with Lewy body dementia (LBD).
- 10 Dec 2018 Status changed from active, no longer recruiting to discontinued, according to an Axovant media release.
- 22 Oct 2018 Status changed from recruiting to active, no longer recruiting.